The Wall Street Journal reports this morning that the big hedge fund SAC Capital Advisors is being investigated for possible insider trading related to AstraZeneca's $15 billion acquisition of MedImmune back in 2007. According to the Journal the SEC has been probing the MedImmune takeover for more than a year, issuing subpoenas as it ponders whether inside info was used to profit from the deal. SAC, a high profile hedge fund, accumulated 796,000 shares of MedImmune in the months ahead of the buyout. Story